mFOLFIRINOX + FOLFIRI

mFOLFIRINOX + FOLFIRI is a combination chemotherapy regimen that consists of two established multi-agent protocols used in the treatment of gastrointestinal cancers, particularly pancreatic cancer. - **mFOLFIRINOX (modified FOLinic acid, Fluorouracil, IRINotecan, and OXaliplatin)** includes oxaliplatin (85 mg/m²), leucovorin (folinic acid; 400 mg/m²), irinotecan (150 mg/m²), and 5-fluorouracil (2400 mg/m² continuous infusion over 46 hours) administered every two weeks. The "modified" version omits or reduces the bolus dose of fluorouracil to reduce toxicity[3][5][6]. - **FOLFIRI** consists of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. It is typically used as a sequential regimen after progression on other therapies or as part of alternating cycles[4]. The combination may be considered for advanced or metastatic pancreatic cancer patients with good performance status who have progressed on prior gemcitabine-based therapy. Both regimens act primarily through cytotoxic mechanisms targeting DNA synthesis and repair in rapidly dividing tumor cells.

Brand names

EloxatinCamptosarAdrucil

Other names

modified FOLFIRINOX plus FOLFIRImFOLFIRINOX and FOLFIRI